Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 36 for your search:
Cancer Type/Condition:
Brain tumor, child: General & other
Stage/Subtype:
recurrent childhood medulloblastoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
2.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
3.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
4.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
5.
Phase I/II Study of MET Tyrosine Kinase Inhibitor PF-02341066 in Children With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0912
, ADVL0912, NCT00939770
6.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
7.
Phase II Study of Bevacizumab and Irinotecan Hydrochloride in Pediatric Patients With Recurrent, Progressive, or Refractory Malignant Glioma (Closed to Accrual as of 4/21/2009), Diffuse or Intrinsic Brain Stem Glioma (Closed to Accrual as of 4/21/2009), Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase:
Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-022
, NCT00381797
8.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
9.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
10.
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
3368
, NCT00576537
11.
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
V0706
, CHRMS# 08-106, PRC # V0706, NCT00601003
12.
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 17 years
Sponsor:
Other
Protocol IDs:
CDR0000066490
, BC-BT-10, NCT00003458
13.
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 17 years
Sponsor:
Other
Protocol IDs:
CDR0000066513
, BC-BT-22, NCT00003476
14.
Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
3 to 70
Sponsor:
Other
Protocol IDs:
MCW-7594
, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
15.
Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0031
, 02-C-0031, 5425, NCI-5425, NCT00030108
16.
Phase I Study of Yttrium Y 90-DOTA-tyr3-Octreotide in Children With Advanced or Refractory Somatostatin Receptor-Positive Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 25
Sponsor:
NCI
Protocol IDs:
UIHC-200008086
, NCI-V02-1710, NCT00049023, 200008086
17.
Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MSKCC-03133
, NCT00089245
18.
Phase I Study of Intra-Arterial Melphalan and Mannitol in Patients With Central Nervous System Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 months and over
Sponsor:
NCI
Protocol IDs:
OHSU-1299
, OHSU-ONC-98018-L, OHSU-4834, NCT00253721
19.
Phase I Study of AZD2171 in Pediatric Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-020
, NCT00326664
20.
Phase I Study of Topotecan Hydrochloride by Convection Enhanced Delivery (Intracerebral Clysis) in Patients With Refractory or Progressive Primary Malignant Brain Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
1 and over
Sponsor:
NCI
Protocol IDs:
CPMC-AAAA-4229
, CPMC-14220, NCT00324844
21.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
22.
Phase I Study of Enzastaurin Hydrochloride in Children and Adolescents With Refractory Primary CNS Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-023
, PBTC-023, NCT00503724
23.
Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
2007-0370
, NCT00513162
24.
Phase I Study of MK0752 in Young Patients With Recurrent or Refractory CNS Malignancies
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
PBTC-024
, PBTC-024, NCI-09-C-0112, NCT00572182
25.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
